MAV will always be a major contributor to the bottom line, but I am with you cosmo. I believe the two sleepers adding significantly to the bottom line will eventually be PIMD and RapiMeds. The November 12th conference is the stage Mr. Schneiderman has been waiting for to let the investing world know about SCRC. It will be exciting to see the results of his efforts.